Chemotherapy-induced nausea and vomiting: Which antiemetic for which therapy?

ONCOLOGY

Volumn 21, Issue 8, 2007, Pages 946-953

  Schwartzberg, Lee S ^a,b  

^a WEST CLINIC   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; BEVACIZUMAB; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CARBOPLATIN; CARMUSTINE; CETUXIMAB; CHLORMETHINE; CHOLINERGIC RECEPTOR; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOLASETRON MESILATE; DOPAMINE RECEPTOR; DRONABINOL; EPIRUBICIN; GEMCITABINE; GRANISETRON; HISTAMINE RECEPTOR; IFOSFAMIDE; IRINOTECAN; NABILONE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; OPIATE RECEPTOR; OXALIPLATIN; PALONOSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN RECEPTOR; STREPTOZOCIN; TRASTUZUMAB; UNINDEXED DRUG;

ANXIETY; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CORTICOSTEROID THERAPY; DIARRHEA; DISTRESS SYNDROME; DIZZINESS; DROWSINESS; DYSPHORIA; EUPHORIA; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; NAUSEA; PARANOIA; PATIENT CARE; PRACTICE GUIDELINE; PROPHYLAXIS; SEDATION; SIDE EFFECT; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; HUMANS; NAUSEA; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 34547138127     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Richardson J, Marks G, Levine A: The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 6:1746-1752, 1988.
2. Craig J, Powell B: The management of nausea and vomiting in clinical oncology. Am J Med Sci 293:34-44, 1987.
3. Siegel L, Longo D: The control of chemotherapy-induced emesis. Ann Intern Med 95:352-359, 1981.
4. Dodds LJ: The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 10:143-166, 1985.
5. Kris M, Gralla R, Clark R, et al: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379-1384, 1985.
6. Jacobsen PB, Redd WH: The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest 6:329-336, 1988.
7. Hesketh P, Kris M, Grunberg S, et al: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997.
8. Grunberg S, Osoba D, Hesketh P, et al: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 13:80-84, 2005.
9. Kris M, Hesketh P, Somerfield M, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006.
10. National Comprehensive Cancer Network: Antiemesis. NCCN Clinical Practice Guidelines in Oncology v.1.2007. Available at www.nccn.org. Accessed June 1, 2007.
11. American Society of Health-System Pharmacists: ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56:729-764, 1999.
12. Grunberg S: Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev 3:216-221, 1989.
13. Gralla R, Roila F, Tonato M, et al: Consensus Conference on Antiemetic Therapy. Multinational Association for Supportive Care in Cancer. Perugia, Italy; March 29-31, 2004.
14. Hesketh P, Navari R, Grote T, et al: Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 14:2242-2249, 1996.
15. Navari R, Gandara D, Hesketh P, et al: Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 13:1242-1248, 1995.
16. Gralla R, Navari R, Hesketh P, et al: Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16:1568-1573, 1998.
17. Perez E, Hesketh P, Sandbach J, et al: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. J Clin Oncol 16:754-760, 1998.
18. Bernard S, Neville K, Nguyen A, et al: Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: Clinical implications. Oncologist 11:126-135, 2006.
19. Kaiser R, Sezer O, Papies A, et al: Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805-2811, 2002.
20. Hickok J, Roscoe J, Morrow G, et al: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880-2886, 2003.
21. Hickok J, Roscoe J, Morrow G, et al: 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: A URCC CCOP randomised controlled trial. Lancet Oncol 6:765-772, 2006.
22. Gralla R, Lichinitser M, Van Der Vegt S, et al: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577, 2003.
23. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al: 99-04 Palonosetron Study Group. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482, 2003.
24. Rubenstein EB, Gralla RJ, Eisenberg P, et al: Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): Combined results of two phase III trials (abstract 2932). Proc Am Soc Clin Oncol 22:729, 2003.
25. Aapro M, Grunberg S, Manikhas G, et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449, 2006.
26. Hajdenberg J, Grote T, Yee L, et al: Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 4:467-471, 2006.
27. Navari R: Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: Summary of clinical trials. Cancer Invest 22:56576, 2004.
28. Massaro A, Lenz K: Aprepitant: A novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 39:77-85, 2005.
29. Hesketh P, Grunberg S, Gralla R, et al: Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003.
30. Warr D, Hesketh P, Gralla R, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005.
31. Hesketh P, Grunberg S, Herrstedt J, et al: Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist induced nausea and vomiting: effect of gender on treatment response. Support Cancer Care 14;354-360, 2006.
32. Navari R, Province P: Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs 11:137-151, 2006.
33. Grote T, Hajdenberg J, Catmell A, et al: Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant. J Support Oncol 4:403-408, 2006.
34. Passik S, Navari R, Jung S, et al: A Phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: A Hoosier Oncology Group Study. Cancer Invest 22:383-388, 2004.
35. Navari R, Einhorn L, Passik S, et al: A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Support Care Cancer 13:529-534, 2005.
36. Martin B, Wiley J: Mechanism of action of cannabinoids: How it may lead to treatment of cachexia, emesis and pain. J Support Oncol 2:305-316, 2004.
37. Davis M, Maida V, Daeninck P, et al: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer 15:63-71, 2007.
38. Tramer M, Carroll D, Campbell F, et al: Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 323:1-8, 2001.
39. Grunberg S, Deuson R, Mavros P, et al: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268, 2004.
40. Bloechl-Daum B, Deuson R, Mavros P, et al: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478, 2006.
41. Herrstedt J: Risk-benefit of antiemetics in the prevention and treatment of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf 3:231-248, 2004.
42. Cohen L, de Moor CA, Eisenberg P, et al: Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings. Support Cancer Care 15:497-503, 2007.
43. Geling O, Eichler H: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289-1294, 2005.
44. de Moor C, Cohen L, Eisenberg P, et al: Oncologists' compliance with antiemetic guidelines (AEG) and outcomes of patients (pts) receiving emetogenic chemotherapy (CT) (abstract 2924). Proc Am Soc Clin Oncol 22:727, 2003.
45. Inbe-Heffinger A, Ehlken B, Bernard R, et al: The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526-536, 2004.